Lactobacillus reuteri may be the single most-researched probiotic strain in periodontal applications. Here's what the trials actually show.
Why L. reuteri Stands Out
If you sort PubMed results by publication count for "probiotic + periodontitis," Lactobacillus reuteri dominates the citations. The interest comes from one specific feature: L. reuteri produces a compound called reuterin — a broad-spectrum antimicrobial that targets several pathogens implicated in periodontal disease while sparing many beneficial mouth bacteria. This selective antimicrobial action makes L. reuteri closer to a "targeted intervention" than most probiotic strains.
How Reuterin Works
Reuterin is produced when L. reuteri metabolizes glycerol. The compound disrupts the cell membranes of susceptible bacteria, particularly gram-negative species. In the periodontal context, this includes some of the bacteria most strongly implicated in chronic gum disease — Porphyromonas gingivalis, Treponema denticola, and similar species. Importantly, the lactobacilli, streptococci, and bifidobacteria that constitute much of a healthy oral microbiome are largely unaffected by reuterin.
Clinical Trial Evidence
Multiple randomized controlled trials have evaluated L. reuteri as an adjunct to scaling-and-root-planing therapy in patients with chronic periodontitis. The pattern across trials: when L. reuteri is added to standard mechanical periodontal treatment, patients tend to show greater reductions in pocket depth, bleeding-on-probing, and inflammatory cytokine levels at 3- and 6-month follow-up than patients receiving mechanical treatment alone. Effect sizes are typically modest to moderate — meaningful, but not dramatic.
Limitations and Caveats
Not every L. reuteri trial has produced statistically significant results. Some have shown only borderline effects; a few have shown none. Differences in study design, patient population (mild vs severe periodontitis), L. reuteri strain (DSM 17938, ATCC PTA 5289, others), and dosing all influence outcomes. The current consensus in the periodontal probiotic literature is "promising adjunct, not a standalone treatment" — meaning L. reuteri is best understood as an addition to professional periodontal care, not a replacement for it.
L. reuteri in Healthy-Mouth Maintenance
Beyond active periodontitis treatment, L. reuteri has also been studied for gingivitis prevention in healthy adults. Trials in this lower-risk population show smaller absolute effects (because the baseline inflammation is lower) but consistent direction — less bleeding, less plaque accumulation, less gum tissue inflammation over months of consistent supplementation. This is the use case most relevant to typical ProDentim users.
Strain Specificity Matters
"L. reuteri" isn't one thing — it's a species with multiple commercially available strains. The strains with the most periodontal research are DSM 17938 and ATCC PTA 5289. When evaluating any oral probiotic claiming L. reuteri, the question to ask is whether the specific strain is identified and whether that strain has indexed research. Generic "L. reuteri" without strain identifier is harder to evaluate.
Combining L. reuteri with Other Strains
In ProDentim's formulation, L. reuteri sits alongside L. paracasei, BLIS K-12, BLIS M-18, and B. lactis BL-04. The rationale is that each strain targets a different aspect of oral microbiome balance — L. reuteri for periodontal support, L. paracasei for general lactobacillus presence, the BLIS strains for breath and plaque, BL-04 for upper respiratory immune support. Multi-strain formulations are not always better than single-strain, but for the broad goal of "oral microbiome maintenance," the multi-strain approach is more defensible than picking one strain alone.
Realistic Timeline
L. reuteri effects on bleeding-on-probing typically appear 3 to 6 weeks into consistent daily use. Pocket-depth changes (when measured by a dentist) take longer — often 8 to 12 weeks. Anti-inflammatory effects in the gum tissue may be measurable in saliva markers within 4 weeks but are gradual to feel subjectively.
Safety
L. reuteri has decades of safety data including infant studies (it's used in some pediatric supplements for colic). Adverse events in periodontal probiotic trials are rare and mild. Standard probiotic safety considerations apply for immunocompromised, antibiotic-treated, or central-line populations.
Bottom Line
L. reuteri is the closest thing to a "reference" oral probiotic strain for gum-related applications. The evidence isn't conclusive enough to position it as a treatment, but it's strong enough to position it as a reasonable adjunct for adults wanting to support gum health alongside daily oral hygiene and regular professional care. ProDentim's inclusion of L. reuteri alongside L. paracasei is one of the formulation choices most aligned with current periodontal probiotic research.
MEDICALLY REVIEWED BY
Dr. Michael Carter, DDS
Doctor of Dental Surgery, 18 years clinical experience. Read full bio →